Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Open accessThe DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index; 27 of the 131 sources its claims cite were checked for support.
Abstract
Guideline article describing standard treatment strategies for colorectal cancer and summarizing evidence-based recommendations.
Overview
CoChat Summary
TL;DR
The JSCCR Guidelines 2016 present consensus-based standard treatment strategies for colorectal cancer in Japan, covering endoscopic and surgical treatment, chemotherapy, radiotherapy, palliative care, and surveillance. They use literature review, GRADE-style evidence assessment, and Delphi consensus to issue recommendations for clinical questions.
Key findings
- Colorectal cancer mortality in Japan surpassed 49,000 in 2015, and deaths per unit population increased approximately tenfold over the past 50 years.
- After curative resection of pStage 0–III colorectal cancer, 5-year survival rates by site were: all sites 82.2%, colon 83.8%, rectosigmoid 81.7%, and Ra–Rb rectum 79.3% (patients treated 2000–2004).
- For rectal cancer with the lower tumor border distal to the peritoneal reflection and invasion beyond the muscularis propria, lateral lymph node metastasis rate was 20.1%; lateral lymph node dissection was expected to reduce intrapelvic recurrence risk by 50% and improve 5-year survival by 8–9%.
- For pT1 (SM) colorectal cancer, the lymph node metastasis rate was 12.5% when submucosal invasion depth was ≥1000 μm; Stage II postoperative adjuvant chemotherapy was not recommended routinely (recommendation/evidence level 1A), while 6 months was the standard duration for 5-FU-based adjuvant chemotherapy (1A).
Methods
- These guidelines were prepared by the JSCCR Guideline Committee by consensus, based on literature searches and consideration of the Japanese health insurance system and clinical practice.
- Literature searches used PubMed and Ichushi-Web from January 2008 to March 2012, with the search period extended to July 2016 for adjuvant chemotherapy and chemotherapy for advanced or recurrent colorectal cancer; 12,000 documents were retrieved (PubMed 7909, Ichushi 4091), and 2320 were selected and critically reviewed.
- Evidence levels and strength of recommendations were assessed with reference to the GRADE system; recommendation strength was determined by Delphi-method voting, with ≥70% committee consensus required.
Limitations
- Stated: the guidelines provide only general recommendations and do not control or limit treatment strategies or methods not described; responsibility for treatment outcomes rests with the personnel directly in charge, not the JSCCR or Guideline Committee.
- Stated: no strength of recommendation was presented in clinical questions, and for several interventions the efficacy and safety were not established, with calls for appropriately planned clinical trials.
- Evident from the text: recommendations are explicitly framed around the Japanese medical insurance system and actual clinical practice in Japan, and the literature search periods ended in 2012 or 2016, so applicability outside Japan or to later evidence is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
14 Valid · 15 Not valid · 52 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Randomized controlled trials involving PS 0 to PS 2 patients have shown that chemotherapy groups have a significantly longer survival time than BSC groups that did not receive anticancer drugs [54–56].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Partly supportedcites [54] Scheithauer W Rosen H Kornek GV Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 1993 306 752 755 10.1136/bmj.306.6880.752 7683942 PMC1677246 sourceExperimental — accuracy not yet measured
The Results report significantly longer survival in the chemotherapy arm than in the supportive-care arm (median 11 versus 5 months; p=0.006). However, Table I groups some participants as PS 2–3, so this trial cannot establish that all participants had PS 0–2. The Results also state that two participants assigned to supportive care later received an anticancer drug. (LLM, conf=0.88)
- Partly supportedcites [55] Simmonds PC Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group BMJ 2000 321 531 535 10.1136/bmj.321.7260.531 10968812 PMC27466 sourceExperimental — accuracy not yet measured
The Survival section reports significantly longer survival for the chemotherapy group in a pooled analysis of randomized trials. However, the paper does not establish that the patients were restricted to PS 0–2, and the Description of studies and Discussion note that some supportive-care patients subsequently received chemotherapy. The claim’s absolute description of the control groups is therefore not supported. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [56] Cunningham D Pyrhonen S James RD Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 1998 352 1413 1418 10.1016/S0140-6736(98)02309-5 9807987 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There are reports showing the efficacy of hepatectomy in patients who have controllable extrahepatic metastases (mainly lung metastases) in addition to liver metastases [35, 36, 39, 43] (CQ-7).”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [35] Murata S Moriya Y Akasu T Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma Cancer 1998 83 1086 1093 10.1002/(SICI)1097-0142(19980915)83:6<1086::AID-CNCR6>3.0.CO;2-6 9740072 doi:10.1002/(sici)1097-0142(19980915)83:6
- Supportedcites [36] Kobayashi K Kawamura M Ishihara T Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer J Thorac Cardiovasc Surg 1999 118 1090 1096 10.1016/S0022-5223(99)70106-6 10595983 source
The Discussion says that synchronous pulmonary metastases should not necessarily be considered a poor prognostic factor for hepatectomy. The paper reports 31% five-year survival after both pulmonary and hepatic resection and concludes that surgery may be appropriate when the metastases are resectable, particularly with a solitary pulmonary metastasis. (LLM, conf=0.90)
- Supportedcites [39] Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–75 (discussion 75–76) 9869759 source
The Conclusions report improved survival after resection of both liver and lung metastases in selected patients with colorectal cancer. This supports the citing sentence’s characterization of the paper as a report of benefit from hepatectomy when lung metastases are also amenable to resection; the finding is limited to selected patients, particularly those with metachronous solitary metastases. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [43] Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–8 (discussion 218–219) 9692467 source
- Not matchedcites CQ-7
This doesn’t read as a citation we can look up.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The incidences of sexual dysfunction and bowel dysfunction were higher in the preoperative radiation combination therapy group than in the surgery-alone group [113, 114].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [113] Marijnen CA van de Velde CJ Putter H Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial J Clin Oncol 2005 23 1847 1858 10.1200/JCO.2005.05.256 15774778 source
- Supportedcites [114] Peeters KC van de Velde CJ Leer JW Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study J Clin Oncol 2005 23 6199 6206 10.1200/JCO.2005.14.779 16135487 source
The Patients section reports more bowel dysfunction after preoperative radiotherapy plus surgery than after surgery alone. The Discussion also reports significantly more sexual dysfunction in irradiated patients, citing a concomitant study by the same group. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“OX increased harmful phenomena in three tests”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [120] Hofheinz RD Wenz F Post S Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial Lancet Oncol 2012 13 579 588 10.1016/S1470-2045(12)70116-X 22503032 source
- Partly supportedcites [122] Aschele C Cionini L Lonardi S Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial J Clin Oncol 2011 29 2773 2780 10.1200/JCO.2010.34.4911 21606427 sourceExperimental — accuracy not yet measured
The Compliance and Acute Toxicity section reports more grade 3–4 adverse events when oxaliplatin was added to preoperative fluorouracil and radiotherapy (24% versus 8%). The Discussion says increased acute toxicity was seen in two randomized phase III trials, not three; the claimed number of tests is unsupported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [123] Gerard JP Azria D Gourgou-Bourgade S Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2 J Clin Oncol 2010 28 1638 1644 10.1200/JCO.2009.25.8376 20194850 source
- Supportedcites [124] Gérard JPAD Gourgou-Bourgade S Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer J Clin Oncol 2012 30 4558 4565 10.1200/JCO.2012.42.8771 23109696 sourceExperimental — accuracy not yet measured
The Discussion reports increased grade 3–4 acute toxicity with oxaliplatin in the ACCORD 12, STAR-01, and NSABP R04 randomized trials. It also notes that the CAO/ARO 04 trial did not show an overall toxicity increase, although one subgroup did. The claim is supported when “harmful phenomena” refers to acute toxicity. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The incidence of acute-phase adverse events was significantly higher in the preoperative chemoradiotherapy groups”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [111] Peeters KC Marijnen CA Nagtegaal ID The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma Ann Surg 2007 246 693 701 10.1097/01.sla.0000257358.56863.ce 17968156 source
- Not checked — no full text of the sourcecites [112] van Gijn W Marijnen CA Nagtegaal ID Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial Lancet Oncol 2011 12 575 582 10.1016/S1470-2045(11)70097-3 21596621 source
- Not checked — no full text of the sourcecites [113] Marijnen CA van de Velde CJ Putter H Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial J Clin Oncol 2005 23 1847 1858 10.1200/JCO.2005.05.256 15774778 source
- Could not verifycites [114] Peeters KC van de Velde CJ Leer JW Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study J Clin Oncol 2005 23 6199 6206 10.1200/JCO.2005.14.779 16135487 sourceExperimental — accuracy not yet measured
The Introduction and Discussion (page unavailable) discuss acute toxicity after preoperative radiotherapy, but the study compares radiotherapy plus surgery with surgery alone and focuses on late side effects. A search for chemoradiotherapy and acute adverse events found no comparison of preoperative chemoradiotherapy with radiotherapy alone in our copy. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [115] Francois Y Nemoz CJ Baulieux J Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial J Clin Oncol 1999 17 2396 10.1200/JCO.1999.17.8.2396 10561302 source
- Supportedcites [116] Bosset JF Collette L Calais G Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 2006 355 1114 1123 10.1056/NEJMoa060829 16971718 source
The Preoperative treatment section reports higher rates of grade 2 and grade 3-or-higher acute toxic effects with preoperative chemoradiotherapy than with radiotherapy alone, with a significant difference (P for trend <0.001). The Discussion likewise says that adding chemotherapy increased acute toxic effects. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [117] Bujko K Nowacki MP Nasierowska-Guttmejer A Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 2006 93 1215 1223 10.1002/bjs.5506 16983741 source
- Not checked — no full text of the sourcecites [118] Gerard JP Conroy T Bonnetain F Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 2006 24 4620 4625 10.1200/JCO.2006.06.7629 17008704 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
81 more claims · 9 with their cited sources checked
Create a free account to see all 130 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 21
- The quote only partly states this claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“No strength of recommendation was presented in CQs.”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“Surgical resection is preferable when the vertical margin is positive (recommendation/evidence level 1C).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“If the distant metastases are unresectable, but the primary tumor is resectable, the indication for the resection of the primary tumor is determined, based on the clinical symptoms of the primary tumor and the impact on the prognosis (CQ-4).”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“CQ-5: resection of the primary tumor in patients with unresectable distant metastases”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
““JSCCR Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer.” [105].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > References
“105. Japanese Society for Cancer of the Colon and Rectum (2016) JSCCR guidelines 2012 for the clinical practice of hereditary colorectal cancer.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“no randomized controlled trials have been implemented regarding whether or not it extends survival [37, 38].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > References
“37. Portier G Elias D Bouche O Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial”
Citations
Cites
Items 201–286 of 286
Green, R. J., Metlay, J. P., Propert, K., Catalano, P. J., Macdonald, J. S., Mayer, R. J., & Haller, D. G. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00005 · Cited by 161 · cited 1×
“• A past history of colorectal cancer, regardless of stage, is a risk factor for metachronous colorectal cancer [134].”
BackgroundFactors influencing survival after complete resection of pulmonary metastases from colorectal cancer
Watanabe, K., Nagai, K., Kobayashi, A., Sugito, M., & Saito, N. (2009) · British Journal of Surgery · doi:10.1002/bjs.6682 · Cited by 160
Kanemitsu, Y., Kato, T., Hirai, T., & Yasui, K. (2004) · British journal of surgery · doi:10.1002/bjs.4370 · Cited by 160
Self-citationDetection and Surveillance of Colorectal Cancer
Ragozzino, M. W. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440030057017 · Cited by 158
Sehgal, A., Keener, C. L., Boynton, A. L., Warrick, J., & Murphy, G. P. (1998) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199810)69:2<60::aid-jso2>3.0.co;2-3 · Cited by 158
High-magnification colonoscopy (with videos)
Tanaka, S., Kaltenbach, T. R., Chayama, K., & Soetikno, R. M. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2006.06.007 · Cited by 158
Self-citationIida, T., Nomori, H., Shiba, M., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826eda3b · Cited by 155
Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer
Kobayashi, K., Kawamura, M., & Ishihara, T. (1999) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70106-6 · Cited by 152 · cited 2×
“• If it is safe and simple to remove the primary lesion and the metastasized lesions in the liver or lungs, resection should also be considered [35, 36].”
BackgroundUeno, H., Mochizuki, H., Hashiguchi, Y., Ishiguro, M., Miyoshi, M., Kajiwara, Y., Sato, T., Shimazaki, H., & Hase, K. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000225359.72553.8c · Cited by 145
Self-citationSurgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review
Rodgers, M., & McCall, J. L. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01580.x · Cited by 142
Mori, T., Takahashi, K., & Yasuno, M. (1998) · Langenbeck s Archives of Surgery · doi:10.1007/s004230050153 · Cited by 142
Self-citationDisappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned?
van Vledder, M. G., Jong, M. C. D., Pawlik, T. M., Schulick, R. D., Diaz, L. A., & Choti, M. A. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1348-y · Cited by 141
Beckurts, K. T. E., Hölscher, A. H., Thorban, S., et al. (1997) · British journal of surgery · doi:10.1046/j.1365-2168.1997.02813.x · Cited by 138
Interval Hepatic Resection of Colorectal Metastases Improves Patient Selection
Lambert, L. (2000) · Archives of Surgery · doi:10.1001/archsurg.135.4.473 · Cited by 133 · cited 1×
“• Some authors believe that resection of liver or lung metastases should be performed only after a certain observation period to rule out occult metastases [40].”
BackgroundSaitoh, Y., Obara, T., Watari, J., Nomura, M., Taruishi, M., Orii, Y., Taniguchi, M., Ayabe, T., Ashida, T., & Kohgo, Y. (1998) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(98)70004-5 · Cited by 132
Hepatectomy for liver metastases
Scheele, J. (1993) · British journal of surgery · doi:10.1002/bjs.1800800302 · Cited by 130
Surveillance after colorectal cancer resection
Berman, J. M., Cheung, R. J., & Weinberg, D. S. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06552-6 · Cited by 124 · cited 1×
“• The recommended interval between colonoscopy ranged from 1 to 5 years, depending on the report [135].”
BackgroundDetection and Surveillance of Colorectal Cancer
Fleischer, D. E. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420040118031 · Cited by 124 · cited 1×
“1 3 gery, that approximately 70% of the recurrences were detected within 2 years after surgery [132, 133]; and that in most patients the recurrences were detected within 5 years after surgery [133].”
BackgroundPrognostic Determinants of Patients With Lateral Nodal Involvement by Rectal Cancer
Ueno, H., Mochizuki, H., Hashiguchi, Y., & Hase, K. (2001) · Annals of Surgery · doi:10.1097/00000658-200108000-00008 · Cited by 122
Self-citationLowry, A. C., Simmang, C. L., Boulos, P., Farmer, C. K., Finan, P. J., Hyman, N., Killingback, M., Lubowski, D. Z., Moore, R., Penfold, C., et al. (2001) · Diseases of the Colon & Rectum · doi:10.1007/bf02235475 · Cited by 121
Long-Term Results of Intersphincteric Resection for Low Rectal Cancer
Yamada, K., 緒方, 俊., Saiki, Y., et al. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31819f5fa2 · Cited by 118
Repeat liver resection for recurrent colorectal liver metastases
Yamamoto, J., Kosuge, T., Shimada, K., et al. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00176-2 · Cited by 113
Self-citationPark, I. J., Kim, H. C., Yu, C. S., Kim, P. N., Won, H. J., & Kim, J. C. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9625-z · Cited by 112 · cited 1×
“There is a high rate of recurrence in comparison to resection, however, and long-term survival is reported to be poor [46], so it is not recommended as an alternative to surgical resection [47] (CQ-12).”
BackgroundBrain metastases from colorectal carcinoma: prognostic factors and outcome
Jung, M., Ahn, J. B., Chang, J. H., Suh, C., Hong, S., Roh, J. K., Shin, S. J., & Rha, S. Y. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0214-9 · Cited by 112
Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer?
Robinson, B. J., Rice, T. W., Strong, S. A., Rybicki, L. A., & Blackstone, E. H. (1999) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(99)70470-8 · Cited by 111 · cited 2×
“1 There are reports showing the efficacy of hepatectomy in patients who have controllable extrahepatic metastases (mainly lung metastases) in addition to liver metastases [35, 36, 39, 43] (CQ-7).”
Backgroundde Santibáñes, E., Lassalle, F. B., McCormack, L., et al. (2002) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(02)01235-8 · Cited by 108
Isolated paraaortic lymph‐node recurrence after the curative resection of colorectal carcinoma
Min, B. S., Kim, N. K., Sohn, S. K., Cho, C. H., Lee, K. Y., & Baik, S. H. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20926 · Cited by 108
Choi, P. W., Kim, H. C., Kim, A. Y., et al. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21421 · Cited by 107
Ike, H., Shimada, H., Ohki, S., et al. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6222-0 · Cited by 107
Discontinuous Rectal Cancer Spread in the Mesorectum and the Optimal Distal Clearance Margin in Situ
Ono, C., Yoshinaga, K., Enomoto, M., & Sugihara, K. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6290-1 · Cited by 106
Self-citationSatoh, T., Ura, T., Yamada, Y., Yamazaki, K., Tsujinaka, T., Munakata, M., Nishina, T., Okamura, S., Esaki, T., Sasaki, Y., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02030.x · Cited by 102
Self-citationMatsuda, T., Fukuzawa, M., Uraoka, T., Nishi, M., Yamaguchi, Y., Kobayashi, N., Ikematsu, H., Saito, Y., Nakajima, T., Fujii, T., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01997.x · Cited by 101
Self-citationImpact of repeat hepatectomy on recurrent colorectal liver metastases
Suzuki, S., Sakaguchi, T., Yokoi, Y., et al. (2001) · Surgery · doi:10.1067/msy.2001.112486 · Cited by 96
Shirao, K., Hoff, P. M., Ohtsu, A., Loehrer, P. J., Hyodo, I., Wadler, S., Wadleigh, R. G., O'Dwyer, P. J., Muro, K., Yamada, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.017 · Cited by 96 · cited 1×
“(2) FOLFIRI [34, 35] ± bevacizumab [36, 37] (3) FOLFOX ± cetuximab/panitumumab [38, 39] (4) FOLFIRI ± cetuximab/panitumumab [40, 41] (5) 5-FU ? LV [42] ± bevacizumab [43, 44] or UFT ? LV [45] FOLFIRI bevacizumab* or CPT-11”
Self-citationIntentionally curative treatment of locally recurrent rectal cancer: a systematic review
Tanis, P. J., Doeksen, A., & van Lanschot, J. J. B. (2013) · Canadian Journal of Surgery · doi:10.1503/cjs.025911 · Cited by 92
Douillard, J., Siena, S., Cassidy, J., Tabernero, J. M., Burkes, R. L., Barugel, M. E., Humblet, Y., Cunningham, D., Wolf, M., & Gansert, J. L. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72039-7 · Cited by 89
Local therapy of rectal tumors
Mentges, B., Bueß, G., Schäfer, D., et al. (1996) · Diseases of the Colon & Rectum · doi:10.1007/bf02053987 · Cited by 86 · cited 1×
“Transanal resection includes the conventional method in which the tumor is resected under direct vision and transanal endoscopic microsurgery (TEM) [11].”
MethodRepeat hepatectomy for recurrent colorectal liver metastases
Pessaux, P., Lermite, É., Bréhant, O., et al. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20384 · Cited by 86
Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 84 · cited 4×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialLuo, F., Liu, X., Yan, N., Li, S., Cao, G., Cheng, Q., Xia, Q., & Wang, H. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-26 · Cited by 80
Resection of hepatic metastases of colorectal carcinoma: 20 years' experience
Nakamura, S., Suzuki, S., & Konno, H. (1999) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340050079 · Cited by 79
Colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up
Cutsem, E. V., & Oliveira, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn077 · Cited by 77
Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp017 · Cited by 76
Tanaka, S., Haruma, K., Oh-E, H., et al. (2000) · Oncology Reports · doi:10.3892/or.7.4.783 · Cited by 76 · cited 1×
“Factors such as the depth of submucosal invasion (SM invasion depth) [80], histological type (such as poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous carcinoma [79]), the presence of a poorly differentiated area and muconodules at the site of deepest invasion, budding, and vascular invas…”
BackgroundSelf-citationRepeat liver resection for recurrent colorectal metastases: a single‐centre, 13‐year experience
Battula, N. R., Tsapralis, D., Mayer, D. A., Isaac, J., Muiesan, P., Sutcliffe, R. P., Bramhall, S. R., Mirza, D. F., & Marudanayagam, R. (2013) · HPB · doi:10.1111/hpb.12096 · Cited by 75
Kogon, M. M., Biswas, A., Pearl, D., Carlson, R. W., & Spiegel, D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970715)80:2<317::aid-cncr21>3.0.co;2-w · Cited by 74
Pathological study of distal mesorectal cancer spread to determine a proper distal resection margin
Zhao, G., 周总光, Lei, W.-Z., Yu, Y.-Y., Wang, C., Wang, Z., Zheng, X.-L., & Wang, R. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i3.319 · Cited by 74
Koga, R., Yamamoto, J., Saiura, A., Yamaguchi, T., Hata, E., & Sakamoto, M. (2006) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyl076 · Cited by 73
Self-citationStereotactic body radiotherapy for isolated paraaorticlymph node recurrence from colorectal cancer
Kim, M., Cho, C. K., Yang, K., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.6091 · Cited by 72
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Study Group for Pulmonary Metastases from Colorectal Cancer, 廣澤, 知., Itabashi, M., et al. (2012) · Surgery Today · doi:10.1007/s00595-012-0373-8 · Cited by 68
Self-citationSakamoto, J., Hamada, C., Yoshida, S., Kodaira, S., Yasutomi, M., Kato, T., Oba, K., Nakazato, H., Saji, S., & Ohashi, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603686 · Cited by 68
Surgery for Synchronous Hepatic Metastases of Colorectal Cancer
Bismuth, H., Castaing, D., & Traynor, O. J. (1988) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528809096972 · Cited by 67
Repeat liver resection for recurrent liver metastases from colorectal cancer
Thelen, A., Jonas, S., Benckert, C., Schumacher, G., Lopez-Hänninen, E., Rudolph, B. D., Neumann, U. P., & Neuhaus, P. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2006.10.016 · Cited by 65
Min, B. S., Kim, J. S., Kim, N. K., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0692-1 · Cited by 64
Ishiguro, S., Akasu, T., Fujimoto, Y., Yamamoto, J., Sakamoto, Y., Sano, T., Shimada, K., Kosuge, T., Yamamoto, S., Fujita, S., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9067-z · Cited by 64
Shimada, Y., Takii, Y., Maruyama, S., & Ohta, T. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e318233fc4a · Cited by 64
Self-citationCurrent Management of Colorectal Liver Metastases
Martin, L. W., & Warren, R. S. (2000) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30126-1 · Cited by 63
Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma
Kanzaki, R., Higashiyama, M., Oda, K., Fujiwara, A., Tokunaga, T., Maeda, J., Okami, J., Tanaka, K., Shingai, T., Noura, S., et al. (2011) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2010.08.016 · Cited by 59
Brain metastasis from colorectal cancer: Prognostic factors and survival
Noura, S., Ohue, M., Shingai, T., et al. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23055 · Cited by 59
Watanabe, T. (2011) · 日本癌治療学会誌 · Cited by 58
Self-citationDeveloping Strategies for Liver Metastases From Colorectal Cancer
Adam, R. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.01.003 · Cited by 58 · cited 1×
“• Systemic chemotherapy is effective in regard to cases of inoperable liver metastasis, with some cases demonstrating that curative resection may become possible [41, 42] (CQ-9).”
BackgroundMechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis
Renehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602369 · Cited by 57 · cited 1×
“Meta-analyses of RCTs conducted in Europe and the United States have shown that surveillance after curative surgical resection of colorectal cancer contributes to improving the resection rate of recurrent tumors and to improving the prognosis [70–74] (CQ-19).”
BackgroundPietrantonio, F., Cremolini, C., Aprile, G., Lonardi, S., Orlandi, A., Mennitto, A., Berenato, R., Antoniotti, C., Casagrande, M., Marsico, V. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0171 · Cited by 57 · cited 2×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
Sastre, J., Massutí, B., Pulido, G., Guillén‐Ponce, C., Benavides, M., Manzano, J. L., Reboredo, M., Rivera, F., Grávalos, C., Safont, M. J., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.013 · Cited by 56
Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis
Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Kobayashi, H., Kotake, K., Funahashi, K., Hase, K., Hirata, K., Iiai, T., Kameoka, S., Kanemitsu, Y., Maeda, K., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0820-3 · Cited by 54
Self-citationOka, S., Tanaka, S., Kanao, H., Ishikawa, H., Watanabe, T., Igarashi, M., Saito, Y., Ikematsu, H., Kobayashi, K., Inoue, Y., et al. (2011) · Digestive Endoscopy · doi:10.1111/j.1443-1661.2010.01072.x · Cited by 52
Self-citationMulti-institutional registry of large bowel cancer in Japan
大腸癌研究会 (1992) · Cited by 51
Nagakura, S., Shirai, Y., Suda, T., & Hatakeyama, K. (2002) · World Journal of Surgery · doi:10.1007/s00268-001-0196-z · Cited by 51
Aprile, G., Zanon, E., Tuniz, F., Iaiza, E., Pauli, F. D., Pella, N., Pizzolitto, S., Buffoli, A., Piga, A., Škrap, M., et al. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0468-1 · Cited by 50
Yoshidome, H., Kimura, F., Shimizu, H., Ohtsuka, M., Kato, A., Yoshitomi, H., Furukawa, K., Mitsuhashi, N., Takeuchi, D., Iida, A., et al. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0540-9 · Cited by 49
Procedures of Choice for Resection of Primary and Recurrent Liver Metastases from Colorectal Cancer
Tanaka, K., Shimada, H., Ohta, M., et al. (2004) · World Journal of Surgery · doi:10.1007/s00268-004-7214-x · Cited by 48
Adjuvant radiotherapy for rectal cancer
Steele, R. J., & Sebag‐Montefiore, D. (1999) · British journal of surgery · doi:10.1046/j.1365-2168.1999.01274.x · Cited by 45
de Reyniès, A., Boige, V., Milano, G. A., Faivre, J., & Laurent‐Puig, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9186 · Cited by 42 · cited 1×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundHaller, D. G., Tabernero, J. M., Maroun, J. A., et al. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72033-6 · Cited by 38
Kobayashi, H., Kotake, K., & Sugihara, K. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0505-6 · Cited by 38
Self-citationEarly nonpolypoid colorectal cancer: radiographic diagnosis of depth of invasion.
Watari, J., Saitoh, Y., Obara, T., et al. (1997) · Radiology · doi:10.1148/radiology.205.1.9314964 · Cited by 36
Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants
PATEL, S. R., Papadopoulos, N. E., Plager, C., Linke, K. A., Moseley, S. H., Spiridonidis, C. H., & Benjamin, R. S. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960815)78:4<773::aid-cncr13>3.0.co;2-s · Cited by 35
Wierzbicki, R. F., Jonker, D. J., Moore, M. J., Berry, S. R., Loehrer, P. J., Youssoufian, H., & Rowinsky, E. K. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9341-6 · Cited by 34 · cited 1×
“A recent report showed that there is no relationship between the effect of anti-EGFR antibody drugs and the level of EGFR expression assessed by immunostaining [91].”
BackgroundPeeters, M., Price, T. J., Hotko, Y., Cervantes, A. M. R., Ducreux, M. P., André, T., Chan, E., Lordick, F., Rong, A., & Gansert, J. L. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)72049-x · Cited by 34
Ozawa, H., Kotake, K., Kobayashi, H., et al. (2013) · Surgery Today · doi:10.1007/s00595-013-0735-x · Cited by 33
Self-citationSiena, S., Tabernero, J. M., Cunningham, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3566 · Cited by 30
Diamond-blackfan anemia and malignancy. A case report and a review of the literature
van Dijken, P. J., & Verwijs, W. (1995) · Cancer · doi:10.1002/1097-0142(19950801)76:3<535::aid-cncr2820760331>3.0.co;2-k · Cited by 28
Survival after surgical treatment of recurrent carcinoma of the rectum.
Tschmelitsch, J., Kronberger, P., Glaser, K., et al. (1994) · PubMed · Cited by 28
Single cerebral metastasis from colorectal adenocarcinoma
D’Andrea, G., Isidori, A., Caroli, E., et al. (2004) · Neurosurgical Review · doi:10.1007/s10143-003-0299-0 · Cited by 15
Peeters, M., Cervantes, A. M. R., Strickland, A. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3565 · Cited by 14
(2000) · doi:10.1002/1097-0142(20000715)89:2
Research works printed but not linked: 1
- Beppu TMT Maeda K Microwave coagulation therapy for metastatic liver tumor Surg Ther 2000 83 237 242
Cited by
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Self-citationRenehan, A. G., Malcomson, L., Emsley, R., Gollins, S., Maw, A., Myint, A. S., Rooney, P. S., Susnerwala, S., Blower, A., Saunders, M. P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00467-2 · Cited by 801
Japanese Society for Cancer of the Colon and Rectum (2019) · Journal of the Anus, Rectum and Colon · doi:10.23922/jarc.2019-018 · Cited by 696
Self-citationAdam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., Sobrero, A., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.006 · Cited by 607
Self-citationJGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection
Tanaka, S., Kashida, H., Saito, Y., Yahagi, N., Yamano, H., Saito, S., Hisabe, T., Yao, T., Watanabe, M., Yoshida, M., et al. (2015) · Digestive Endoscopy · doi:10.1111/den.12456 · Cited by 597
Self-citation
Metadata
- Authors
- Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., Ishihara, S., Kanemitsu, Y., Kawano, H., Kinugasa, Y., Kokudo, N., Murofushi, K., Nakajima, T., Oka, S., Sakai, Y., Tsuji, A., Uehara, K., Ueno, H., Yamazaki, K., Yoshida, M., Yoshino, T., Boku, N., Fujimori, T., Itabashi, M., Koinuma, N., Morita, T., Nishimura, G., Sakata, Y., Shimada, Y., Takahashi, K., Tanaka, S., Tsuruta, O., Yamaguchi, T., Yamaguchi, N., Tanaka, T., Kotake, K., & Sugihara, K.
- Affiliations
- The University of Tokyo (JP)
- Aichi Cancer Center (JP)
- Niigata University (JP)
- National Cancer Center Hospital (JP)
- Saitama Medical Center, Saitama Medical University (JP)
- Tokyo Medical and Dental University (JP)
- St Mary's Hospital (JP)
- Shizuoka Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- St. Marianna University School of Medicine (JP)
- Kyoto University (JP)
- Kagawa University (JP)
- National Defense Medical College (JP)
- National Cancer Center Hospital East (JP)
- Shinko Hospital (JP)
- Tokyo Women's Medical University (JP)
- Aomori Prefectural Central Hospital (JP)
- Misawa City Hospital (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Kurume University (JP)
- Seirei Sakura Citizen Hospital (JP)
- Tochigi Cancer Center (JP)
- Corresponding author
- Watanabe, Toshiaki
- ORCID
- Watanabe, Toshiaki
- Muro, Kei
- Ajioka, Yoichi
- Hashiguchi, Yojiro
- Saito, Yutaka
- Hamaguchi, Tetsuya
- Ishiguro, Megumi
- Ishihara, Soichiro
- Kanemitsu, Yukihide
- Kinugasa, Yusuke
- Murofushi, Keiko
- Nakajima, Takako
- Oka, Shiro
- Sakai, Yoshiharu
- Uehara, Keisuke
- Ueno, Hideki
- Yamazaki, Kentaro
- Yoshida, Masahiro
- Yoshino, Takayuki
- Boku, Narikazu
- Itabashi, Michio
- Morita, Takayuki
- Shimada, Yasuhiro
- Takahashi, Keiichi
- Tanaka, Shinji
- Tanaka, Toshiaki
- Kotake, Kenjiro
- Sugihara, Kenichi
- Venue
- International Journal of Clinical Oncology
- Published
- 2017-03-27
- Volume
- 23
- Issue
- 1
- Pages
- 1-34
- ISSN
- 1341-9625 (ISSN-L)
- 1437-7772
- PMC
- PMC5809573
- OpenAlex
- W1990423062
- Cited by
- 2,467
- References
- 285
- Citations by year
- 2026: 15 · 2025: 106 · 2024: 243 · 2023: 256 · 2022: 270 · 2021: 343 · 2020: 322 · 2019: 234 · 2018: 144 · 2017: 116
- FWCI
- 98.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Journal of Clinical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K08691, 15K10150, 17K10655)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- colorectal cancer, treatment guidelines, clinical practice variation, informed consent, classification of evidence, clinical questions, health insurance system, Japan
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Japan, Liver Neoplasms, Lymph Node Excision, Laparoscopy, Rectal Neoplasms, Colorectal Neoplasms, Chemotherapy, Adjuvant, Dose Fractionation, Radiation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.